The Scientist

» Pfizer

Most Recent

image: Pfizer to Buy Medivation for $14 Billion

Pfizer to Buy Medivation for $14 Billion

By | August 22, 2016

The pharma giant is purchasing the San Francisco–based cancer drugmaker to boost its oncology portfolio.

0 Comments

image: NYU Halts Studies, Suspends Investigator

NYU Halts Studies, Suspends Investigator

By | June 28, 2016

Experiments conducted at the New York University School of Medicine violated several research standards, according to US Food and Drug Administration investigators.

2 Comments

image: Pfizer Scoops Anacor for $5.3 Billion

Pfizer Scoops Anacor for $5.3 Billion

By | May 17, 2016

The acquisition-hungry pharmaceutical firm is purchasing the California-based eczema gel maker.

0 Comments

image: Pfizer-Allergan Merger Scrapped

Pfizer-Allergan Merger Scrapped

By | April 7, 2016

A move by the US federal government to close tax loopholes that encourage “tax inversions” likely spooked the companies out of the multibillion dollar deal.

0 Comments

image: Pfizer and Allergan to Merge

Pfizer and Allergan to Merge

By | November 23, 2015

The two drugmakers will join forces in a $160 billion deal—if it’s given the regulatory green light.

0 Comments

image: Pfizer to Acquire Hospira

Pfizer to Acquire Hospira

By | February 5, 2015

The pharmaceutical giant is purchasing the injectable drugmaker for about $15 billion.

0 Comments

image: Pfizer Scientist Dies

Pfizer Scientist Dies

By | January 25, 2013

Genetics researcher and senior vice president of the pharmaceutical giant, David Cox, has passed away unexpectedly at age 66.

0 Comments

image: First Drug from GM Plant Approved

First Drug from GM Plant Approved

By | May 4, 2012

A human enzyme grown in carrot cells will treat patients with Gaucher disease.

10 Comments

image: Lipitor Patent Expires

Lipitor Patent Expires

By | November 30, 2011

The pharmaceutical darling that has brought billions in revenue to Pfizer over the past 15 years will now share the shelves with its generic competitors.

0 Comments

Popular Now

  1. Opinion: Why I Published in a Predatory Journal
    News & Opinion Opinion: Why I Published in a Predatory Journal

    My “colleagues” and I at the fictitious Arthur Vandelay Urological Research Institute were surprised to find our bogus “uromycitisis” case report swiftly accepted, with only minor revisions requested.

  2. Consilience, Episode 3: Cancer, Obscured
  3. March for Science: Dispatches from Washington, DC
  4. Record-Setting Corn Grows 45 Feet Tall
AAAS